Dayang Chem (Hangzhou) Co., Ltd.
China
Product Name: H-MET-GLU-VAL-GLY-TRP-TYR-ARG-PRO-PRO-PHE-SER-ARG-VAL-VAL-HIS-LEU-TYR-ARG-ASN-GLY-LYS-OH
Price: $Inquiry/100g $Inquiry/1kg $Inquiry/100kg $Inquiry/1000kg
Purity: 98.0%
Stocking Period: Inquiry
Contact: Ms Wang

163158-19-8

163158-19-8 structure

Name: MOG (35-55), human
Chemical Name: h-met-glu-val-gly-trp-tyr-arg-pro-pro-phe-ser-arg-val-val-his-leu-tyr-arg-asn-gly-lys-oh
CAS Number: 163158-19-8
Molecular Formula: C₁₂₀H₁₇₉N₃₅O₂₈S
Molecular Weight: 2591.99000
Catalog: Research Areas Neurological Disease
Create Date: 2018-12-22 14:13:20
Modify Date: 2024-01-09 17:01:43
MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide[1].

Name	h-met-glu-val-gly-trp-tyr-arg-pro-pro-phe-ser-arg-val-val-his-leu-tyr-arg-asn-gly-lys-oh
Synonyms	h2n-mevgwyrppfsrvvhlyrngk-oh myelin oligodendrocyte glycoprotein precursor

Description	MOG (35-55), human is a component of CNS myelin. MOG (35-55), human is different from mMOG (35-55) by a proline for serine substitution at position 42. MOG (35-55), human is also immunogenic, but not encephalitogenic, and is only partially cross-reactive with mMOG35–55. MOG (35-55), human induces minimal clinical signs of EAE relative to the rodent peptide[1].
Related Catalog	Signaling Pathways >> Others >> Others Research Areas >> Neurological Disease
References	[1]. Cathleen Rich, et al. Myelin oligodendrocyte glycoprotein-35-55 peptide induces severe chronic experimental autoimmune encephalomyelitis in HLA-DR2-transgenic mice. Eur J Immunol. 2004 May;34(5):1251-61. [2]. Alfred R Oliver, et al.Rat and human myelin oligodendrocyte glycoproteins induce experimental autoimmune encephalomyelitis by different mechanisms in C57BL/6 mice. J Immunol. 2003 Jul 1;171(1):462-8.